About 70 percent of pregnant women in the United States take a dietary supplement. The NIH Office of Dietary Supplements reports that figure from an analysis of national survey data gathered between 2001 and 2014. It is one of the few numbers in this subject nobody argues about.
Nearly everything downstream of it is argued about. On one nutrient, the federal panel that grades preventive services has issued its strongest possible recommendation. On another, the same panel has twice concluded it cannot tell whether the intervention helps or harms. The leading American obstetric body recommends that second nutrient anyway. Both positions are current.
What follows reports what each body says, with its date and reasoning, and leaves the disagreements standing. Every figure here is a population reference value set by a committee, not a dose for a person. These numbers belong in a conversation with an obstetric clinician.
One thing is worth setting up front, because it inverts how most people read the topic. In pregnancy, the guidance about what to avoid is better evidenced and more consequential than the guidance about what to add.
The one recommendation that carries the strongest federal grade
The US Preventive Services Task Force gives folic acid an A. That is the top grade in its system, reserved for services where it finds high certainty of substantial net benefit. The final recommendation is dated August 1, 2023, and it reaffirms a January 2017 statement that reached the same conclusion.
The published dose range is 400 to 800 micrograms a day, which the statement writes as 0.4 to 0.8 mg. The timing is the part most coverage flattens. The Task Force describes starting at least one month before anticipated conception and continuing through the first two to three months of pregnancy. The neural tube closes in the first weeks after conception, often before a person knows there is anything to close. That is why a recommendation aimed at preventing neural tube defects is written for people who could become pregnant rather than for people who are.
The Task Force also names who the recommendation does not cover: people who have had a previous pregnancy affected by a neural tube defect, people at very high risk for other reasons such as family history, and people taking drugs that block folic acid’s function, named as methotrexate, carbamazepine and valproic acid. The Office of Dietary Supplements reports a much higher figure for high-risk pregnancies, 4,000 to 5,000 micrograms a day, which is five to twelve times the general range and is a clinical decision rather than a shelf decision.
On harms, the Task Force found adequate evidence that folic acid at usual doses is not associated with serious harms. Its review found no statistically significant association with autism spectrum disorder, and no difference in twin deliveries between 4 mg and 0.4 mg daily. Article 358 covers how a population clause works: the folic acid grade is an A for a group defined by the possibility of pregnancy, not an A for everyone.
Iron, where two American bodies read the same evidence differently
Here the agreement ends. The Task Force published its current position in JAMA on September 17, 2024, under the names of Wanda Nicholson, Michael Silverstein, John Wong and colleagues. The population is asymptomatic pregnant adolescents and adults. The conclusion is two separate I statements, meaning insufficient evidence: one for screening for iron deficiency and iron deficiency anemia, one for routine supplementation. The panel states that the balance of benefits and harms in asymptomatic pregnant persons cannot be determined.
That is not a new verdict. The 2024 statement replaced one published in Annals of Internal Medicine on October 6, 2015, which carried the same two I statements. The scope did change. The 2015 version addressed iron deficiency anemia; the 2024 version covers iron deficiency with or without anemia. So the Task Force widened the question and reached the same answer.
The same 2024 statement carries the prevalence numbers, drawn from survey data collected between 1999 and 2006. Iron deficiency is the leading cause of anemia in pregnancy. Overall prevalence during pregnancy is near 18 percent, and it climbs across the three trimesters, from 6.9 percent to 14.3 percent to 28.4 percent. An estimated 5 percent of pregnant people have iron deficiency anemia.
The American College of Obstetricians and Gynecologists reaches a different practical conclusion. Its positions are reported here through the Office of Dietary Supplements fact sheet for health professionals, which carries them attributed. ACOG recommends low-dose iron supplementation for all pregnant women starting in the first trimester, with dose and form not specified. It also recommends screening every pregnant woman for anemia twice, in the first trimester and again at 24 to 28 weeks. For a pregnant woman already diagnosed with iron deficiency anemia, it recommends iron in addition to a prenatal vitamin.
Why the split? The two bodies are answering different questions. The Task Force asks whether screening or routine supplementation, applied to asymptomatic people, has been shown to change maternal and infant outcomes. A professional college writes guidance for obstetricians who must do something at a first prenatal visit, and for whom treating diagnosed anemia is not in dispute. An I statement is a verdict on evidence, not an instruction to withhold care.
The Office of Dietary Supplements sits over the top of both, and its pregnancy fact sheet prints two statements about iron excess that sit under different subheadings. The first opens the iron section, immediately after the observation that iron-containing supplements reduce the risk of iron deficiency and iron deficiency anemia in pregnancy and are recommended by many experts: where a pregnant woman is already iron-replete, ODS says routine supplementation may carry adverse health effects of its own. It names what the underlying studies found, which is a link between iron supplementation or high iron status in iron-replete pregnant women and gestational diabetes, preterm birth and impaired fetal growth. Further down, under the sheet’s own heading for iron and pregnancy, the wording is more cautious: while supplementation in pregnant women with iron deficiency has proven benefits, the benefits and harms of routine supplementation in iron-replete women are uncertain. Both sentences are on the page, and between them the sheet gives the shape: “These findings suggest a U-shaped risk of adverse health effects with both iron deficiency and iron excess.”
The excess is measured, not hypothetical. The iron upper limit in pregnancy is 45 mg a day for ages 14 and older, against a pregnancy RDA of 27 mg, and ODS reports that 27.9 percent of pregnant women in the United States, about one in four, exceed that upper limit once iron from food and supplements is counted together. The fact sheet defines anemia in pregnancy as hemoglobin below 10.5 to 11 g/dL depending on trimester, which is a laboratory threshold a clinician applies, not a self-assessment. Article 330 covers iron more generally.
What the guidance warns against, and why that matters more
Preformed vitamin A is the clearest case in the whole subject, and it runs in the opposite direction from everything above.
Preformed vitamin A is the version found in animal foods, supplements and some medicines, often listed as retinyl palmitate or retinyl acetate. The Office of Dietary Supplements states that total intakes above the upper limit, as well as some retinoid medicines used as topical therapies, can cause congenital birth defects, and that those defects can include malformations of the eye, skull, lungs and heart.
Beta-carotene is a different molecule with a different record. The same fact sheet states that unlike preformed vitamin A, beta-carotene is not known to be teratogenic, meaning capable of causing malformations in a developing fetus, or to cause reproductive toxicity. A label listing vitamin A as beta-carotene is not making the same claim as one listing it as retinyl palmitate.
Two numbers appear here and they are not the same number. The fact sheet reports an advisory that experts tell women who are or might be pregnant, and those who are lactating, not to take high doses of vitamin A supplements, with high dose defined as more than 3,000 micrograms RAE, equal to 10,000 international units, a day. Separately, the tolerable upper intake level for preformed vitamin A in pregnancy is 2,800 micrograms a day for ages 14 to 18 and 3,000 micrograms for ages 19 and over. Those pregnancy figures carry the same scope ODS attaches to every preformed vitamin A limit, which article 355 sets out: food and supplements counted together, and only the preformed kind. For a pregnant teenager, the upper limit is below the advisory threshold. Reporting one figure and calling it the other blurs a real difference. Article 323 covers the upper limit concept itself.
What the fact sheet does not supply is a dose-response risk estimate. No published figure there says how much the risk of a birth defect rises per unit of excess intake.
Iodine: societies agree, products vary widely
Iodine is where the professional bodies line up and the products do not.
The Office of Dietary Supplements puts the iodine RDA at 220 micrograms a day in pregnancy and 290 micrograms during lactation. It writes that “During pregnancy and early infancy, iodine deficiency can cause irreversible effects.” Severe chronic deficiency in the womb causes cretinism, a syndrome of intellectual disability with motor and growth problems. The mechanism is simple: early in pregnancy the fetal thyroid is still forming, so the fetus depends entirely on maternal thyroxine.
On supplementation, the fact sheet reports that the American Thyroid Association advises women who are planning pregnancy, pregnant or lactating to supplement with 150 micrograms a day of iodine as potassium iodide, and that the American Academy of Pediatrics recommends a daily supplement containing at least 150 micrograms plus the use of iodized salt.
Now the product side, where the primary research is sharper than the agency summary. A study published in Thyroid, the journal of the American Thyroid Association, examined the top-selling prenatal multivitamins sold in the United States between July 2016 and July 2017. Of the 59 products analyzed, 34 contained iodine. The median was 150 micrograms per daily serving, matching the recommendation, but the range ran from 25 to 290 micrograms. Weighted by what people bought, the picture gets worse: of roughly 467 million prenatal doses sold that year, 76.8 percent contained iodine, which means close to a quarter of prenatal doses sold in America carried none at all. Among the iodine-containing products, 73.5 percent used potassium iodide and 23.5 percent used kelp, which the authors identify as a source known to be highly variable. Two of the six authors list the supplement industry’s trade association, the Council for Responsible Nutrition, among their affiliations.
The honest trade-off belongs here too. Supplementation trials giving 150 to 200 micrograms a day in early pregnancy found no effect on children’s cognitive, language or motor scores, and a 2010 Spanish study found that pregnant women taking 200 micrograms a day or more had significantly higher risk of raised thyroid stimulating hormone than women taking under 100. Deficiency has a documented harm; supplementation above a point has a signal of its own. The iodine upper limit is 1,100 micrograms a day for adults 19 and over including pregnant and lactating women, and 900 micrograms for ages 14 to 18.
Botanical ingredients and the sentence that keeps recurring
Read any federal or federally supported page on herbal products in pregnancy and the same structural sentence appears: there is limited information on the use of most of these products during pregnancy.
MotherToBaby, a service of the Organization of Teratology Information Specialists, publishes the clearest consumer-facing version. It is supported by the Health Resources and Services Administration under an award totaling $1,200,000, with zero percent financed by non-governmental sources, so it is federally rather than commercially funded. Its herbal products fact sheet is dated April 1, 2025.
Its points, reordered by how much they matter to a reader: dangerous side effects have been reported for some herbal products; very few have scientific proof that they work as labeled; FDA regulates them differently from prescription medicines and there are no standards for ingredient content or strength; products may contain contaminants including lead, arsenic and mercury; and products may contain ingredients not listed on the label. On nursing, the sheet is blunter still, noting there is little information on use of herbal products while breastfeeding.
This is where tradition and evidence have to be kept apart. Long use is a historical fact about a plant, not a safety finding about a pregnancy, because the outcome that matters here, fetal development, was never systematically recorded across the centuries that long use refers to.
Prenatal products themselves sometimes carry these ingredients. The Office of Dietary Supplements notes that some prenatal supplements contain botanical ingredients and others such as probiotics, and that many of these have not been thoroughly studied in pregnant women. A product labeled prenatal is not thereby a product studied in pregnancy.
Breastfeeding, counted from the mother’s side
CDC’s page for health professionals on maternal diet and breastfeeding was last reviewed and updated on August 25, 2026. It covers the mother. Article 335 covers infant supplementation, including the pediatric vitamin D figure, and that material is not repeated here.
A well-nourished breastfeeding mother needs an additional 330 to 400 kilocalories a day compared with her intake before pregnancy. CDC names six micronutrients whose requirements rise during lactation: vitamin B12, folate, vitamin D, vitamin A, iodine and choline. The lactation figures it gives are 290 micrograms a day of iodine and 550 milligrams a day of choline.
The clearest transfer case is vitamin B12, because milk content tracks maternal status. CDC states that breastfed infants of women who do not consume any animal products may have very limited amounts of vitamin B12, and that low amounts can put infants at risk of neurological damage from deficiency. The Office of Dietary Supplements adds that this can appear sometimes very early in life, that untreated deficiency in infants can cause neurological damage alongside failure to thrive, developmental delay and anemia, and, crucially, that the mother’s own deficiency may be mild and go unrecognized. The published lactation RDA for B12 is 2.8 micrograms a day against 2.6 in pregnancy. For a mother eating no animal foods, this is the situation that warrants a clinician’s attention, because the mother can look fine while the infant does not.
Iodine transfers too. ODS reports a Boston study suggesting about 47 percent of women may have supplied insufficient iodine through breast milk.
CDC frames the supplement question carefully. It states that diet alone may not ensure adequate nutrition for breastfeeding women, and that health care providers should work with breastfeeding women to determine appropriate dietary supplements during lactation. That is a routing statement rather than a product recommendation.
The product is a separate question from the nutrient
Everything above concerns nutrients. Whether a given bottle contains what it says is a different inquiry, and in prenatal products it has been measured, if only in small samples.
The Office of Dietary Supplements reports a 2023 Government Accountability Office review of 12 over-the-counter prenatal products. Eleven of the 12 contained at least one nutrient at an amount outside acceptable deviations from its label value, judged against US Pharmacopeia thresholds. Six of the 12 contained trace lead or cadmium, though GAO judged these not to be at levels likely to cause a health concern on FDA metrics. A separate Canadian analysis of 51 samples from 26 prenatal supplements found 14 samples with lead above the US Pharmacopeia limit, and three above known upper limits for aluminum and inorganic arsenic.
Twelve products is not a prevalence estimate, and neither is 26. These illustrate a failure mode rather than measuring how common it is. Article 350 covers contamination across the supplement market, and articles 346 and 351 cover what testing marks verify.
One formulation detail has a direct consequence. The Office of Dietary Supplements notes that gummy formulations often contain no iron, and elsewhere that they often contain no iron or calcium. A gummy prenatal and a tablet prenatal can carry the same category name and a different nutrient list.
Questions that change an answer at an appointment
Most of the uncertainty above cannot be resolved by reading a label harder. A short list, built from where the published positions diverge:
- Which of these nutrients is being recommended for me because of a test result, and which because of a general population recommendation?
- Have I been screened for iron deficiency or anemia, and what did the hemoglobin value show?
- Does the product I am taking contain preformed vitamin A, and in what amount and form?
- Does it contain iodine, and how much?
- Does it contain any botanical ingredient or probiotic, and is there pregnancy data on that specific ingredient?
- For nursing: does anything about my diet change what reaches the milk?
The single most useful thing to carry out of all this is the shape of the evidence rather than any one number. One nutrient, folic acid, has the strongest grade American preventive medicine awards, and its window opens before most pregnancies are known. One nutrient, iron, has sat at insufficient evidence for a decade while a major obstetric college recommends it anyway, and both of those are defensible readings of the same literature. One nutrient, preformed vitamin A, has a documented teratogenic effect above a stated intake, and that is the figure where the published guidance is least ambiguous. And an entire category, botanicals, mostly has no pregnancy data at all, which is a different situation from having reassuring data. Knowing which of those four situations a given ingredient is in tells you more than any single milligram figure.
Keep exploring: herbs to avoid during pregnancy.
Sources
- National Institutes of Health, Office of Dietary Supplements. “Dietary Supplements and Life Stages: Pregnancy (Health Professional Fact Sheet).” ods.od.nih.gov
- National Institutes of Health, Office of Dietary Supplements. “Dietary Supplements and Life Stages: Pregnancy (Consumer Fact Sheet).” ods.od.nih.gov
- National Institutes of Health, Office of Dietary Supplements. “Vitamin A and Carotenoids (Health Professional Fact Sheet).” ods.od.nih.gov
- National Institutes of Health, Office of Dietary Supplements. “Iodine (Health Professional Fact Sheet).” ods.od.nih.gov
- National Institutes of Health, Office of Dietary Supplements. “Vitamin B12 (Health Professional Fact Sheet).” ods.od.nih.gov
- U.S. Preventive Services Task Force. “Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication (Final Recommendation Statement, August 1, 2023; Grade A).” uspreventiveservicestaskforce.org
- Centers for Disease Control and Prevention. “Maternal Diet and Breastfeeding (page for health professionals; last reviewed and updated August 25, 2026).” cdc.gov
- MotherToBaby, Organization of Teratology Information Specialists (supported by HRSA/HHS). “Herbal Products and Pregnancy (fact sheet dated April 1, 2025; page modified December 2, 2025).” mothertobaby.org
- U.S. Preventive Services Task Force (Nicholson WK, Silverstein M, Wong JB, et al.). “"Screening and Supplementation for Iron Deficiency and Iron Deficiency Anemia During Pregnancy: US Preventive Services Task Force Recommendation Statement." JAMA 2024;332(11):906-913, published September 17, 2024. PubMed PMID 39163015. DOI: 10.1001/jama.2024.15196.” pubmed.ncbi.nlm.nih.gov
- U.S. Preventive Services Task Force (Siu AL). “"Screening for Iron Deficiency Anemia and Iron Supplementation in Pregnant Women to Improve Maternal Health and Birth Outcomes: U.S. Preventive Services Task Force Recommendation Statement." Ann Intern Med 2015;163(7):529-536, published October 6, 2015. PubMed PMID 26344176. DOI: 10.7326/M15-1707.” pubmed.ncbi.nlm.nih.gov
- Patel A, Lee SY, Stagnaro-Green A, MacKay D, Wong AW, Pearce EN (Boston University School of Medicine; two authors affiliated with the Council for Responsible Nutrition). “"Iodine Content of the Best-Selling United States Adult and Prenatal Multivitamin Preparations." Thyroid 2019;29(1):124-127, published online October 30, 2018. PubMed PMID 30266075. DOI: 10.1089/thy.2018.0386.” pubmed.ncbi.nlm.nih.gov